Private placement of Aryx stock sends shares soaring(0)
Aryx Therapeutics, the Fremont biopharamaceutical whose shares were slammed last July when Procter & Gamble pulled out of a partnership in developing Aryx’s drug to treat chronic constipation and abdominal pain, said today that it had raised $21.6 million through a private placement of about 9.6 million shares, along with the sale of warrants good on a potential 2.9 million additional shares.
The purchase price for the new shares was pegged at Read the rest of this entry »
Subscribe via RSS all feeds